The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Turuspekova S.T.

S.D. Asfendiyarov Kazakh National Medical University

Nurguzhaev E.S.

S.D. Asfendiyarov Kazakh National Medical University

Nurzhanova R.B.

S.D. Asfendiyarov Kazakh National Medical University

Demesinova B.C.

S.D. Asfendiyarov Kazakh National Medical University

Karimov G.K.

City Clinical Hospital No. 7

Dyusembaeva Z.B.

City Clinical Hospital No. 7

Mamashayev N.K.

S.D. Asfendiyarov Kazakh National Medical University

Myrzamuratova D.

S.D. Asfendiyarov Kazakh National Medical University

Modern aspects of chronic cerebral ischemia pathogenetic therapy

Authors:

Turuspekova S.T., Nurguzhaev E.S., Nurzhanova R.B., Demesinova B.C., Karimov G.K., Dyusembaeva Z.B., Mamashayev N.K., Myrzamuratova D.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(12): 106‑113

DOI: 10.17116/jnevro2024124121106

Read: 2808 times

Contact the author
Table of contents

MODERN ASPECTS OF CHRONIC CEREBRAL ISCHEMIA PATHOGENETIC THERAPY
MODERN ASPECTS OF CHRONIC CEREBRAL ISCHEMIA PATHOGENETIC THERAPY

To cite this article:

Turuspekova ST, Nurguzhaev ES, Nurzhanova RB, et al. Modern aspects of chronic cerebral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(12):106‑113. (In Russ.)
https://doi.org/10.17116/jnevro2024124121106

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cardiogenic deme­ntia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):43-49
Comparative study of the neuroprotective effe­cts of the drug Cyto­flavin and citi­coline in a rats model of hemo­rrhagic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):85-95
Targets of rational neuroprotection in the therapy of chro­nic cere­bral ischemia and the possibilities of achieving them. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):96-101
Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):133-139
Epileptogenesis and risk factors of symptomatic epileptic seizures in patients with acute cere­brovascular acci­dents. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):26-31
Resu­lts of the inte­rnational multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the effi­cacy and safety of the sequential therapy with ethy­lmethylhydroxypyridine succinate in patients in the acute and early reco­very periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53
Effe­ctiveness of “brain—computer” inte­rfaces with biofeedback in the reha­bilitation of cognitive impairment after a stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):54-60
Asso­ciation of the ischemic heart disease with blood pressure, age and work expe­rience in men with shift work in the Far North. Russian Journal of Preventive Medi­cine. 2025;(8):34-40
Asse­ssment of biomarker levels in patients with STEMI, depe­nding on the presence of cardiovascular events. Russian Journal of Preventive Medi­cine. 2025;(8):96-101
The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(4):49-59
Abstract:

Chronic cerebral ischemia (CCI) is one of the most common forms of cerebrovascular disease, which affects a significant number of patients, often leading to disability, cognitive impairment and dementia. The analysis of modern data on the pathogenesis and risk factors for the development of CCI, as well as on the mechanisms of action of Mexidol on various links in the pathogenesis of CCI. A systematic search was conducted in the PubMed, MEDLINE and Google Scholar databases, on Russian and English-language sites with open access publications on the problem of CCI and on the drug Mexidol in the period from 2014 to 2024. The analysis included randomized controlled trials, meta-analyses and original studies, excluded low-confidence studies, retrospective studies, literature reviews, systematic reports and descriptions of clinical cases. It has been established that the use of Mexidol leads to a significant regression of cognitive, emotional, autonomic and motor disorders in CCI. An important indicator of the effectiveness of Mexidol is the high degree of patient adherence to therapy. It is recommended to start treatment with injection of Mexidol, followed by a transition to tablet forms.

Keywords:

chronic cerebral ischemia
cognitive impairment
arterial hypertension
cerebrovascular diseases
Mexidol
neuroprotection
neurology

Authors:

Turuspekova S.T.

S.D. Asfendiyarov Kazakh National Medical University

Nurguzhaev E.S.

S.D. Asfendiyarov Kazakh National Medical University

Nurzhanova R.B.

S.D. Asfendiyarov Kazakh National Medical University

Demesinova B.C.

S.D. Asfendiyarov Kazakh National Medical University

Karimov G.K.

City Clinical Hospital No. 7

Dyusembaeva Z.B.

City Clinical Hospital No. 7

Mamashayev N.K.

S.D. Asfendiyarov Kazakh National Medical University

Myrzamuratova D.

S.D. Asfendiyarov Kazakh National Medical University

Received:

19.11.2024

Accepted:

06.12.2024

Close metadata

References:

  1. Zakharov VV, Vakhina NV. Diagnosis and treatment of chronic cerebral ischemia (clinical analysis). Meditsinskiy sovet. 2018;18:44-49. (In Russ.). https://doi.org/10.21518/2079-701X-2018-18-44-49
  2. Turuspekova ST, Nurguzhaev ES, Nurzhanova RB, et al. Chronic cerebral ischemia: modern approaches to therapy (literature review). Medicina (Almaty). 2021;4(226):28-38. (In Russ.).
  3. Vygovskaya SN, Nuvakhova MB, Doroginina AY, et al. Chronic cerebral ischemia — from correct diagnosis to adequate therapy. Rossiyskiy meditsinskiy zhurnal. 2015;12:694. (In Russ.).
  4. World Health Organization. WHO reveals leading causes of death and disability worldwide 2000-2019. 2020. Accessed October 03, 2017. https://www.who.int/ru/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019
  5. Parfenov VA. Discirculatory encephalopathy and vascular cognitive disorders. M.: IMA-PRESS; 2017. (In Russ.).
  6. Saji N, Ogama N, Toba K, et al. White matter hyperintensities and geriatric syndrome: An important role of arterial stiffness. Geriatr Gerontol Int. 2015;15 Suppl 1:17-25.  https://doi.org/10.1111/ggi.12673
  7. Anbar R, Jones S, Chaturvedi N, et al. Associations of carotid atherosclerosis with cognitive function and brain health: Findings from a UK tri-ethnic cohort study. Atheroscler Plus. 2024;55:39-46.  https://doi.org/10.1016/j.athplu.2024.01.002
  8. Suri S, Mackay CE, Kelly ME, et al. Reduced cerebrovascular reactivity in young adults carrying the APOE ε4 allele. Alzheimers Dement. 2015;11(6):648-657.e1.  https://doi.org/10.1016/j.jalz.2014.05.1755
  9. Kazibwe R, Schaich CL, Muhammad AI, et al. Effect of vigorous-intensity physical activity on incident cognitive impairment in high-risk hypertension. Alzheimer’s Dement. 2024;27(7):1-11.  https://doi.org/10.1002/alz.13887
  10. Dhana A, DeCarli C, Dhana K, et al. Association of Subjective Memory Complaints With White Matter Hyperintensities and Cognitive Decline Among Older Adults in Chicago. JAMA Netw Open. 2022;5(4):e227512. https://doi.org/10.1001/jamanetworkopen.2022.7512
  11. Suri S, Chiesa ST, Zsoldos E, et al. Longitudinal aortic stiffness is associated with brain microstructure and cognition: A voxel-wise magnetic resonance imaging study. Alzheimer’s Dement. 2020;16:e041822. https://doi.org/10.1002/alz.041822
  12. Chamorro A, Dirnagl U, Urra X, et al. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurology. 2016;15(18):869-881.  https://doi.org/10.1017/cjn.2021.223
  13. Ramanathan M, Abdul KK, Justin A. Low dose of L-glutamic acid attenuated the neurological dysfunctions and excitotoxicity in bilateral common carotid artery occluded mice. Behav Pharmacol. 2016;27(7):615-622.  https://doi.org/10.1097/fbp.0000000000000256
  14. Bon EI, Maksimovich NE. The role of excitotoxicity in the pathogenesis of brain damage in ischemia. Vestnik Smolenskoi Gosudarstvennoi Meditsinskoi Akademii. 2019;18(1):67-72. (In Russ.).
  15. Vakhnina NV, Zakharov VV. Gait disturbances and postural stability in dyscirculatory encephalopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(1):78-84. (In Russ.). https://doi.org/10.17116/jnevro20171171178-84
  16. Dotsenko NY, Boev SS, Shekhunova IA, et al. Arterial hypertension as a risk factor for cognitive impairment and secondary prevention. Therapia. 2015;7-8:100. (In Russ.).
  17. Petersen RC. Mild Cognitive Impairment. Continuum (Minneap Minn). 2016;22(2):404-418.  https://doi.org/10.1212/CON.0000000000000313
  18. Levin OS. Diagnosis and treatment of cognitive impairments and dementia in clinical practice. M.: MedPressinform, 2023. (In Russ.).
  19. Starchina YA, Zakharov VV. Severity and therapy of cognitive impairments. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2021;13(3):119-124. (In Russ.). https://doi.org/10.14412/2074-2711-2021-3-119-124
  20. Turuspekova ST, Atantaeva EB, Nurgaliyeva LB, et al. Arterial hypertension as a predictor of dementia syndrome. Medicine (Almaty). 2016;9(171):75-82. (In Russ.).
  21. Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Cognitive disorders. M.: Remedium Group, 2014. (In Russ.).
  22. Kamchatnov PR, Vorobyeva OV, Rachin AP. Correction of emotional and cognitive impairments in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(4):52-56. (In Russ.).
  23. Lokshina AB. Severe dementia: diagnosis, patient management, complication prevention. Rossiiskii Psikhiatricheskii Zhurnal. 2017;4:53-60. (In Russ.).
  24. Kurbanova MM, Galaeva AA, Stefanovskaya EV, et al. Modern methods of cognitive impairment diagnostics. Rossiiskii Semeinyi Vrach. 2020;24(1):35-44. (In Russ.).
  25. Seitz D, Chan C, Newton H, et al. Mini-cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a primary care setting. Cochrane Database Syst Rev. 2018;2(2):CD011415. https://doi.org/10.1002/14651858.cd011415.pub2
  26. Pinto T, Machado L, Bulgacov T, et al. Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer’s Disease (AD) in the elderly? Int Psychogeriatr. 2019;31(4):491-504.  https://doi.org/10.1017/s1041610218001370
  27. Arevalo-Rodriguez I, Smailagic N, Roqué-i-Figuls M, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer’s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;2015(3):CD010783. https://doi.org/10.1002/14651858.cd010783.pub2
  28. Voronina TA. Pioneer of antioxidant neuroprotection. 20 years in clinical practice. Russkii meditsinskii zhurnal. 2016;7:434-438. (In Russ.).
  29. Mikhaylova SA. Neuroprotection in arterial hypertension and transient ischemic attack. Mexidol in clinic and experiment. M., RNMOT. 2019;214-215. (In Russ.).
  30. Gromova OA, Torshin IY, Stelmashuk EV, et al. Study of Mexidol’s neuroprotective effect in a cellular model of glutamate stress. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(12):71-77. (In Russ.). https://doi.org/10.17116/jnevro201711712171-77
  31. Bereznaya SV, Yakupov EZ, Zakharov YA. The efficacy of combined therapy with Mexidol and Cerebrolysin in chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(5):23-27. (In Russ.). https://doi.org/10.17116/jnevro20161165123-27
  32. Gromova OA, Torshin IY, Stakhovskaya LV, et al. Experience of Mexidol application in neurological practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10):97-107. (In Russ.). https://doi.org/10.17116/jnevro201811810197
  33. Chukanova EI, Chukanova AS, Mamaeva HI. Results of the study on the efficacy and safety of Mexidol in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;2:71-74. (In Russ.). https://doi.org/10.17116/jnevro20151152171-74
  34. Chukanova EI, Chukanova AS. Efficacy and safety of Mexidol FORTE 250 in the framework of sequential therapy in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119:939-945. (In Russ.). https://doi.org/10.17116/jnevro201911909139
  35. Gribacheva IA, Popova TF, Petrova EV, et al. Opportunities for multimodal neuroprotection in patients with chronic cerebral ischemia against the background of arterial hypertension and atherosclerosis. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2023;15(2):19-26. (In Russ.). https://doi.org/10.14412/2074-2711-2023-2-19-26
  36. Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of the international multicenter randomized double-blind placebo-controlled study evaluating the efficacy and safety of sequential therapy in patients with chronic cerebral ischemia with Mexidol and Mexidol FORTE 250 (MEMO study). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
  37. Zakharov VV, Tkacheva ON, Mkhitaryan EA, et al. Efficacy of Mexidol in patients of different age groups with chronic cerebral ischemia and cognitive impairments (results of the subanalysis of the international multicenter randomized double-blind placebo-controlled MEMO study). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11-2):73-80. (In Russ.). https://doi.org/10.17116/jnevro202212211273
  38. Zakharov VV, Ostroumova OD, Kochetkov AI, et al. International multicenter randomized double-blind placebo-controlled study evaluating the efficacy and safety of sequential therapy in patients with chronic cerebral ischemia with Mexidol® and Mexidol® FORTE 250 (MEMO study): results of the subanalysis in patients with arterial hypertension. Terapiya. 2023;9(1):145-159. (In Russ.). https://doi.org/10.18565/therapy.2023.1.145-159
  39. Ushkalova EA, Zyryanov SK, Butranova OI. Safety of Mexidol® (ethylmethylhydroxypyridine succinate) in adult patients of different age groups. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(5):77-82. (In Russ.). https://doi.org/10.14412/2074-2711-2022-5-77-82
  40. Martynov AI, Tanashyan MM, Malyavin AG, et al. Resolution of the Expert Council «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders». Terapija. 2023;9(10):148-158. (In Russ.). https://doi.org/10.18565/therapy.2023.10.148-158
  41. Zhuravleva MV, Kamchatnov PR, Vasyukova NS, et al. Results of clinical studies on the efficacy and safety of ethylmethylhydroxypyridinosuccinate in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11):29-39. (In Russ.). https://doi.org/10.17116/jnevro202212211129
  42. Antipenko EA, Shulyndin AV, Belyakov KM. Neurometabolic therapy of moderate cognitive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3):42-51. (In Russ.). https://doi.org/10.17116/jnevro202412403142
  43. Vizilo TL, Arefieva EG. Improving the effectiveness of pharmacotherapy in comorbid patients with chronic cerebral ischemia in outpatient settings. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(3):51-55. (In Russ.). https://doi.org/10.17116/jnevro202312303151
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.